| For: | Xia Y, Hu Y, Ma JH. Premixed insulin: Advantages, disadvantages, and future. World J Diabetes 2025; 16(3): 102526 [PMID: 40093285 DOI: 10.4239/wjd.v16.i3.102526] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v16/i3/102526.htm |
| Number | Citing Articles |
| 1 |
Miao Yu. iGlarLixi: A titrateable fixed‐ratio combination of basal insulin + GLP‐1 receptor agonist—An effective type 2 diabetes treatment option in China. Diabetes, Obesity and Metabolism 2025; 27(S10) doi: 10.1111/dom.70192
|
| 2 |
Petek Eylul Taneri, Yang Guo, Brenda Bongaerts, Jennifer Manne-Goehler, Gojka Roglic, Camila Micaela Escobar Liquitay, Nandi L Siegfried, Juan VA Franco. Insulin regimens for adults living with type 1 diabetes mellitus. Cochrane Database of Systematic Reviews 2026; 2026(5) doi: 10.1002/14651858.CD016351
|
| 3 |
Eveline M Anto, Adheena M, P. Jayamurthy. ER stress: A putative therapeutic target for diabetes mellitus. Biochemical and Biophysical Research Communications 2026; 818 doi: 10.1016/j.bbrc.2026.153773
|